Table of Content

1 Report Overview
1.1 Influenzavirus B Infection Drug Definition
1.2 Market by Type
1.2.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 APP-309
1.2.3 CF-403
1.2.4 GC-3106A
1.2.5 KIN-1400
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Influenzavirus B Infection Drug Sales
2.1 Global Influenzavirus B Infection Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Influenzavirus B Infection Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Influenzavirus B Infection Drug Revenue by Region
2.3.1 Global Influenzavirus B Infection Drug Revenue by Region (2018-2023)
2.3.2 Global Influenzavirus B Infection Drug Revenue by Region (2024-2034)
2.4 Global Influenzavirus B Infection Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Influenzavirus B Infection Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Influenzavirus B Infection Drug Sales Quantity by Region
2.6.1 Global Influenzavirus B Infection Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Influenzavirus B Infection Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Influenzavirus B Infection Drug Sales Quantity by Manufacturers
3.1.1 Global Influenzavirus B Infection Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Influenzavirus B Infection Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Influenzavirus B Infection Drug Sales in 2024
3.2 Global Influenzavirus B Infection Drug Revenue by Manufacturers
3.2.1 Global Influenzavirus B Infection Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Influenzavirus B Infection Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Influenzavirus B Infection Drug Revenue in 2024
3.3 Global Influenzavirus B Infection Drug Sales Price by Manufacturers
3.4 Global Key Players of Influenzavirus B Infection Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Influenzavirus B Infection Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Influenzavirus B Infection Drug, Product Offered and Application
3.8 Global Key Manufacturers of Influenzavirus B Infection Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Influenzavirus B Infection Drug Sales Quantity by Type
4.1.1 Global Influenzavirus B Infection Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Influenzavirus B Infection Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Influenzavirus B Infection Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Influenzavirus B Infection Drug Revenue by Type
4.2.1 Global Influenzavirus B Infection Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Influenzavirus B Infection Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Influenzavirus B Infection Drug Revenue Market Share by Type (2018-2034)
4.3 Global Influenzavirus B Infection Drug Price by Type
4.3.1 Global Influenzavirus B Infection Drug Price by Type (2018-2023)
4.3.2 Global Influenzavirus B Infection Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Influenzavirus B Infection Drug Sales Quantity by Application
5.1.1 Global Influenzavirus B Infection Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Influenzavirus B Infection Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Influenzavirus B Infection Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Influenzavirus B Infection Drug Revenue by Application
5.2.1 Global Influenzavirus B Infection Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Influenzavirus B Infection Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Influenzavirus B Infection Drug Revenue Market Share by Application (2018-2034)
5.3 Global Influenzavirus B Infection Drug Price by Application
5.3.1 Global Influenzavirus B Infection Drug Price by Application (2018-2023)
5.3.2 Global Influenzavirus B Infection Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Influenzavirus B Infection Drug Sales by Company
6.1.1 North America Influenzavirus B Infection Drug Revenue by Company (2018-2023)
6.1.2 North America Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023)
6.2 North America Influenzavirus B Infection Drug Market Size by Type
6.2.1 North America Influenzavirus B Infection Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Influenzavirus B Infection Drug Revenue by Type (2018-2034)
6.3 North America Influenzavirus B Infection Drug Market Size by Application
6.3.1 North America Influenzavirus B Infection Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Influenzavirus B Infection Drug Revenue by Application (2018-2034)
6.4 North America Influenzavirus B Infection Drug Market Size by Country
6.4.1 North America Influenzavirus B Infection Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Influenzavirus B Infection Drug Revenue by Country (2018-2034)
6.4.3 North America Influenzavirus B Infection Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Influenzavirus B Infection Drug Sales by Company
7.1.1 Europe Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Influenzavirus B Infection Drug Revenue by Company (2018-2023)
7.2 Europe Influenzavirus B Infection Drug Market Size by Type
7.2.1 Europe Influenzavirus B Infection Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Influenzavirus B Infection Drug Revenue by Type (2018-2034)
7.3 Europe Influenzavirus B Infection Drug Market Size by Application
7.3.1 Europe Influenzavirus B Infection Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Influenzavirus B Infection Drug Revenue by Application (2018-2034)
7.4 Europe Influenzavirus B Infection Drug Market Size by Country
7.4.1 Europe Influenzavirus B Infection Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Influenzavirus B Infection Drug Revenue by Country (2018-2034)
7.4.3 Europe Influenzavirus B Infection Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Influenzavirus B Infection Drug Sales by Company
8.1.1 China Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023)
8.1.2 China Influenzavirus B Infection Drug Revenue by Company (2018-2023)
8.2 China Influenzavirus B Infection Drug Market Size by Type
8.2.1 China Influenzavirus B Infection Drug Sales Quantity by Type (2018-2034)
8.2.2 China Influenzavirus B Infection Drug Revenue by Type (2018-2034)
8.3 China Influenzavirus B Infection Drug Market Size by Application
8.3.1 China Influenzavirus B Infection Drug Sales Quantity by Application (2018-2034)
8.3.2 China Influenzavirus B Infection Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Influenzavirus B Infection Drug Sales by Company
9.1.1 APAC Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Influenzavirus B Infection Drug Revenue by Company (2018-2023)
9.2 APAC Influenzavirus B Infection Drug Market Size by Type
9.2.1 APAC Influenzavirus B Infection Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Influenzavirus B Infection Drug Revenue by Type (2018-2034)
9.3 APAC Influenzavirus B Infection Drug Market Size by Application
9.3.1 APAC Influenzavirus B Infection Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Influenzavirus B Infection Drug Revenue by Application (2018-2034)
9.4 APAC Influenzavirus B Infection Drug Market Size by Region
9.4.1 APAC Influenzavirus B Infection Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Influenzavirus B Infection Drug Revenue by Region (2018-2034)
9.4.3 APAC Influenzavirus B Infection Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Influenzavirus B Infection Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Influenzavirus B Infection Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Influenzavirus B Infection Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 AbbVie Inc
11.1.1 AbbVie Inc Company Information
11.1.2 AbbVie Inc Overview
11.1.3 AbbVie Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 AbbVie Inc Influenzavirus B Infection Drug Products and Services
11.1.5 AbbVie Inc Influenzavirus B Infection Drug SWOT Analysis
11.1.6 AbbVie Inc Recent Developments
11.2 Adimmune Corp
11.2.1 Adimmune Corp Company Information
11.2.2 Adimmune Corp Overview
11.2.3 Adimmune Corp Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Adimmune Corp Influenzavirus B Infection Drug Products and Services
11.2.5 Adimmune Corp Influenzavirus B Infection Drug SWOT Analysis
11.2.6 Adimmune Corp Recent Developments
11.3 Altravax Inc
11.3.1 Altravax Inc Company Information
11.3.2 Altravax Inc Overview
11.3.3 Altravax Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Altravax Inc Influenzavirus B Infection Drug Products and Services
11.3.5 Altravax Inc Influenzavirus B Infection Drug SWOT Analysis
11.3.6 Altravax Inc Recent Developments
11.4 Amarillo Biosciences Inc
11.4.1 Amarillo Biosciences Inc Company Information
11.4.2 Amarillo Biosciences Inc Overview
11.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Products and Services
11.4.5 Amarillo Biosciences Inc Influenzavirus B Infection Drug SWOT Analysis
11.4.6 Amarillo Biosciences Inc Recent Developments
11.5 Aphios Corp
11.5.1 Aphios Corp Company Information
11.5.2 Aphios Corp Overview
11.5.3 Aphios Corp Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Aphios Corp Influenzavirus B Infection Drug Products and Services
11.5.5 Aphios Corp Influenzavirus B Infection Drug SWOT Analysis
11.5.6 Aphios Corp Recent Developments
11.6 BioCryst Pharmaceuticals Inc
11.6.1 BioCryst Pharmaceuticals Inc Company Information
11.6.2 BioCryst Pharmaceuticals Inc Overview
11.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Products and Services
11.6.5 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug SWOT Analysis
11.6.6 BioCryst Pharmaceuticals Inc Recent Developments
11.7 Cadila Healthcare Ltd
11.7.1 Cadila Healthcare Ltd Company Information
11.7.2 Cadila Healthcare Ltd Overview
11.7.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Products and Services
11.7.5 Cadila Healthcare Ltd Influenzavirus B Infection Drug SWOT Analysis
11.7.6 Cadila Healthcare Ltd Recent Developments
11.8 ContraFect Corp
11.8.1 ContraFect Corp Company Information
11.8.2 ContraFect Corp Overview
11.8.3 ContraFect Corp Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 ContraFect Corp Influenzavirus B Infection Drug Products and Services
11.8.5 ContraFect Corp Influenzavirus B Infection Drug SWOT Analysis
11.8.6 ContraFect Corp Recent Developments
11.9 Daiichi Sankyo Company Ltd
11.9.1 Daiichi Sankyo Company Ltd Company Information
11.9.2 Daiichi Sankyo Company Ltd Overview
11.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Products and Services
11.9.5 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug SWOT Analysis
11.9.6 Daiichi Sankyo Company Ltd Recent Developments
11.10 Fujifilm Holdings Corporation
11.10.1 Fujifilm Holdings Corporation Company Information
11.10.2 Fujifilm Holdings Corporation Overview
11.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Products and Services
11.10.5 Fujifilm Holdings Corporation Influenzavirus B Infection Drug SWOT Analysis
11.10.6 Fujifilm Holdings Corporation Recent Developments
11.11 GlaxoSmithKline Plc
11.11.1 GlaxoSmithKline Plc Company Information
11.11.2 GlaxoSmithKline Plc Overview
11.11.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Products and Services
11.11.5 GlaxoSmithKline Plc Recent Developments
11.12 Green Cross Corp
11.12.1 Green Cross Corp Company Information
11.12.2 Green Cross Corp Overview
11.12.3 Green Cross Corp Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Green Cross Corp Influenzavirus B Infection Drug Products and Services
11.12.5 Green Cross Corp Recent Developments
11.13 Inovio Pharmaceuticals Inc
11.13.1 Inovio Pharmaceuticals Inc Company Information
11.13.2 Inovio Pharmaceuticals Inc Overview
11.13.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Products and Services
11.13.5 Inovio Pharmaceuticals Inc Recent Developments
11.14 Kineta Inc
11.14.1 Kineta Inc Company Information
11.14.2 Kineta Inc Overview
11.14.3 Kineta Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 Kineta Inc Influenzavirus B Infection Drug Products and Services
11.14.5 Kineta Inc Recent Developments
11.15 Medicago Inc
11.15.1 Medicago Inc Company Information
11.15.2 Medicago Inc Overview
11.15.3 Medicago Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Medicago Inc Influenzavirus B Infection Drug Products and Services
11.15.5 Medicago Inc Recent Developments
11.16 MedImmune LLC
11.16.1 MedImmune LLC Company Information
11.16.2 MedImmune LLC Overview
11.16.3 MedImmune LLC Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.16.4 MedImmune LLC Influenzavirus B Infection Drug Products and Services
11.16.5 MedImmune LLC Recent Developments
11.17 Mucosis BV
11.17.1 Mucosis BV Company Information
11.17.2 Mucosis BV Overview
11.17.3 Mucosis BV Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.17.4 Mucosis BV Influenzavirus B Infection Drug Products and Services
11.17.5 Mucosis BV Recent Developments
11.18 Novavax Inc
11.18.1 Novavax Inc Company Information
11.18.2 Novavax Inc Overview
11.18.3 Novavax Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.18.4 Novavax Inc Influenzavirus B Infection Drug Products and Services
11.18.5 Novavax Inc Recent Developments
11.19 Park Active Molecules
11.19.1 Park Active Molecules Company Information
11.19.2 Park Active Molecules Overview
11.19.3 Park Active Molecules Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.19.4 Park Active Molecules Influenzavirus B Infection Drug Products and Services
11.19.5 Park Active Molecules Recent Developments
11.20 Romark Laboratories LC
11.20.1 Romark Laboratories LC Company Information
11.20.2 Romark Laboratories LC Overview
11.20.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.20.4 Romark Laboratories LC Influenzavirus B Infection Drug Products and Services
11.20.5 Romark Laboratories LC Recent Developments
11.21 Sanofi
11.21.1 Sanofi Company Information
11.21.2 Sanofi Overview
11.21.3 Sanofi Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.21.4 Sanofi Influenzavirus B Infection Drug Products and Services
11.21.5 Sanofi Recent Developments
11.22 Sanofi Pasteur SA
11.22.1 Sanofi Pasteur SA Company Information
11.22.2 Sanofi Pasteur SA Overview
11.22.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.22.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Products and Services
11.22.5 Sanofi Pasteur SA Recent Developments
11.23 Shionogi & Co Ltd
11.23.1 Shionogi & Co Ltd Company Information
11.23.2 Shionogi & Co Ltd Overview
11.23.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.23.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Products and Services
11.23.5 Shionogi & Co Ltd Recent Developments
11.24 SK Chemicals Co Ltd
11.24.1 SK Chemicals Co Ltd Company Information
11.24.2 SK Chemicals Co Ltd Overview
11.24.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.24.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Products and Services
11.24.5 SK Chemicals Co Ltd Recent Developments
11.25 TSRL Inc
11.25.1 TSRL Inc Company Information
11.25.2 TSRL Inc Overview
11.25.3 TSRL Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.25.4 TSRL Inc Influenzavirus B Infection Drug Products and Services
11.25.5 TSRL Inc Recent Developments
11.26 Vaxart Inc
11.26.1 Vaxart Inc Company Information
11.26.2 Vaxart Inc Overview
11.26.3 Vaxart Inc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.26.4 Vaxart Inc Influenzavirus B Infection Drug Products and Services
11.26.5 Vaxart Inc Recent Developments
11.27 Vectura Group Plc
11.27.1 Vectura Group Plc Company Information
11.27.2 Vectura Group Plc Overview
11.27.3 Vectura Group Plc Influenzavirus B Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.27.4 Vectura Group Plc Influenzavirus B Infection Drug Products and Services
11.27.5 Vectura Group Plc Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Influenzavirus B Infection Drug Value Chain Analysis
12.2 Influenzavirus B Infection Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Influenzavirus B Infection Drug Production Mode & Process
12.4 Influenzavirus B Infection Drug Sales and Marketing
12.4.1 Influenzavirus B Infection Drug Sales Channels
12.4.2 Influenzavirus B Infection Drug Distributors
12.5 Influenzavirus B Infection Drug Customers
13 Market Dynamics
13.1 Influenzavirus B Infection Drug Industry Trends
13.2 Influenzavirus B Infection Drug Market Drivers
13.3 Influenzavirus B Infection Drug Market Challenges
13.4 Influenzavirus B Infection Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of APP-309
Table 3. Major Manufacturers of CF-403
Table 4. Major Manufacturers of GC-3106A
Table 5. Major Manufacturers of KIN-1400
Table 6. Major Manufacturers of Others
Table 7. Global Influenzavirus B Infection Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Influenzavirus B Infection Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Influenzavirus B Infection Drug Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2018-2023)
Table 11. Global Influenzavirus B Infection Drug Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2024-2034)
Table 13. Global Influenzavirus B Infection Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 14. Global Influenzavirus B Infection Drug Sales by Region (2018-2023) & (K Pcs)
Table 15. Global Influenzavirus B Infection Drug Sales Market Share by Region (2018-2023)
Table 16. Global Influenzavirus B Infection Drug Sales by Region (2024-2034) & (K Pcs)
Table 17. Global Influenzavirus B Infection Drug Sales Market Share by Region (2024-2034)
Table 18. Global Influenzavirus B Infection Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 19. Global Influenzavirus B Infection Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 20. Global Influenzavirus B Infection Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 21. Global Influenzavirus B Infection Drug Revenue Share by Manufacturers (2018-2023)
Table 22. Global Influenzavirus B Infection Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 23. Global Key Players of Influenzavirus B Infection Drug, Industry Ranking, 2021 VS 2024
Table 24. Global Influenzavirus B Infection Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Influenzavirus B Infection Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenzavirus B Infection Drug as of 2024)
Table 26. Global Key Manufacturers of Influenzavirus B Infection Drug, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Influenzavirus B Infection Drug, Product Offered and Application
Table 28. Global Key Manufacturers of Influenzavirus B Infection Drug, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Influenzavirus B Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 31. Global Influenzavirus B Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 32. Global Influenzavirus B Infection Drug Sales Quantity Share by Type (2018-2023)
Table 33. Global Influenzavirus B Infection Drug Sales Quantity Share by Type (2024-2034)
Table 34. Global Influenzavirus B Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 35. Global Influenzavirus B Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Influenzavirus B Infection Drug Revenue Share by Type (2018-2023)
Table 37. Global Influenzavirus B Infection Drug Revenue Share by Type (2024-2034)
Table 38. Influenzavirus B Infection Drug Price by Type (2018-2023) & (USD/Pcs)
Table 39. Global Influenzavirus B Infection Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 40. Global Influenzavirus B Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 41. Global Influenzavirus B Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 42. Global Influenzavirus B Infection Drug Sales Quantity Share by Application (2018-2023)
Table 43. Global Influenzavirus B Infection Drug Sales Quantity Share by Application (2024-2034)
Table 44. Global Influenzavirus B Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 45. Global Influenzavirus B Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Influenzavirus B Infection Drug Revenue Share by Application (2018-2023)
Table 47. Global Influenzavirus B Infection Drug Revenue Share by Application (2024-2034)
Table 48. Influenzavirus B Infection Drug Price by Application (2018-2023) & (USD/Pcs)
Table 49. Global Influenzavirus B Infection Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 50. North America Influenzavirus B Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 51. North America Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 52. North America Influenzavirus B Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 53. North America Influenzavirus B Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 54. North America Influenzavirus B Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 55. North America Influenzavirus B Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Influenzavirus B Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 57. North America Influenzavirus B Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 58. North America Influenzavirus B Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 59. North America Influenzavirus B Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Influenzavirus B Infection Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 61. North America Influenzavirus B Infection Drug Revenue by Country (2018-2023) & (US$ Million)
Table 62. North America Influenzavirus B Infection Drug Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Influenzavirus B Infection Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 64. North America Influenzavirus B Infection Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 65. Europe Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 66. Europe Influenzavirus B Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 67. Europe Influenzavirus B Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 68. Europe Influenzavirus B Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 69. Europe Influenzavirus B Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 70. Europe Influenzavirus B Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Influenzavirus B Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 72. Europe Influenzavirus B Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 73. Europe Influenzavirus B Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 74. Europe Influenzavirus B Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Influenzavirus B Infection Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 76. Europe Influenzavirus B Infection Drug Revenue by Country (2018-2023) & (US$ Million)
Table 77. Europe Influenzavirus B Infection Drug Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Influenzavirus B Infection Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 79. Europe Influenzavirus B Infection Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 80. China Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 81. China Influenzavirus B Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 82. China Influenzavirus B Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 83. China Influenzavirus B Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 84. China Influenzavirus B Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 85. China Influenzavirus B Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Influenzavirus B Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 87. China Influenzavirus B Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 88. China Influenzavirus B Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 89. China Influenzavirus B Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 91. APAC Influenzavirus B Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 92. APAC Influenzavirus B Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 93. APAC Influenzavirus B Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 94. APAC Influenzavirus B Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 95. APAC Influenzavirus B Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Influenzavirus B Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 97. APAC Influenzavirus B Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 98. APAC Influenzavirus B Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 99. APAC Influenzavirus B Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Influenzavirus B Infection Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 101. APAC Influenzavirus B Infection Drug Revenue by Region (2018-2023) & (US$ Million)
Table 102. APAC Influenzavirus B Infection Drug Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Influenzavirus B Infection Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 104. APAC Influenzavirus B Infection Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 105. Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 106. Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 108. Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 109. Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 110. Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 112. Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 113. Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Country (2018-2023) & (US$ Million)
Table 117. Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 119. Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 120. AbbVie Inc Company Information
Table 121. AbbVie Inc Description and Overview
Table 122. AbbVie Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 123. AbbVie Inc Influenzavirus B Infection Drug Product and Services
Table 124. AbbVie Inc Influenzavirus B Infection Drug SWOT Analysis
Table 125. AbbVie Inc Recent Developments
Table 126. Adimmune Corp Company Information
Table 127. Adimmune Corp Description and Overview
Table 128. Adimmune Corp Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 129. Adimmune Corp Influenzavirus B Infection Drug Product and Services
Table 130. Adimmune Corp Influenzavirus B Infection Drug SWOT Analysis
Table 131. Adimmune Corp Recent Developments
Table 132. Altravax Inc Company Information
Table 133. Altravax Inc Description and Overview
Table 134. Altravax Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 135. Altravax Inc Influenzavirus B Infection Drug Product and Services
Table 136. Altravax Inc Influenzavirus B Infection Drug SWOT Analysis
Table 137. Altravax Inc Recent Developments
Table 138. Amarillo Biosciences Inc Company Information
Table 139. Amarillo Biosciences Inc Description and Overview
Table 140. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 141. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product and Services
Table 142. Amarillo Biosciences Inc Influenzavirus B Infection Drug SWOT Analysis
Table 143. Amarillo Biosciences Inc Recent Developments
Table 144. Aphios Corp Company Information
Table 145. Aphios Corp Description and Overview
Table 146. Aphios Corp Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 147. Aphios Corp Influenzavirus B Infection Drug Product and Services
Table 148. Aphios Corp Influenzavirus B Infection Drug SWOT Analysis
Table 149. Aphios Corp Recent Developments
Table 150. BioCryst Pharmaceuticals Inc Company Information
Table 151. BioCryst Pharmaceuticals Inc Description and Overview
Table 152. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 153. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product and Services
Table 154. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug SWOT Analysis
Table 155. BioCryst Pharmaceuticals Inc Recent Developments
Table 156. Cadila Healthcare Ltd Company Information
Table 157. Cadila Healthcare Ltd Description and Overview
Table 158. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 159. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product and Services
Table 160. Cadila Healthcare Ltd Influenzavirus B Infection Drug SWOT Analysis
Table 161. Cadila Healthcare Ltd Recent Developments
Table 162. ContraFect Corp Company Information
Table 163. ContraFect Corp Description and Overview
Table 164. ContraFect Corp Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 165. ContraFect Corp Influenzavirus B Infection Drug Product and Services
Table 166. ContraFect Corp Influenzavirus B Infection Drug SWOT Analysis
Table 167. ContraFect Corp Recent Developments
Table 168. Daiichi Sankyo Company Ltd Company Information
Table 169. Daiichi Sankyo Company Ltd Description and Overview
Table 170. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 171. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product and Services
Table 172. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug SWOT Analysis
Table 173. Daiichi Sankyo Company Ltd Recent Developments
Table 174. Fujifilm Holdings Corporation Company Information
Table 175. Fujifilm Holdings Corporation Description and Overview
Table 176. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 177. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product and Services
Table 178. Fujifilm Holdings Corporation Influenzavirus B Infection Drug SWOT Analysis
Table 179. Fujifilm Holdings Corporation Recent Developments
Table 180. GlaxoSmithKline Plc Company Information
Table 181. GlaxoSmithKline Plc Description and Overview
Table 182. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 183. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product and Services
Table 184. GlaxoSmithKline Plc Recent Developments
Table 185. Green Cross Corp Company Information
Table 186. Green Cross Corp Description and Overview
Table 187. Green Cross Corp Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 188. Green Cross Corp Influenzavirus B Infection Drug Product and Services
Table 189. Green Cross Corp Recent Developments
Table 190. Inovio Pharmaceuticals Inc Company Information
Table 191. Inovio Pharmaceuticals Inc Description and Overview
Table 192. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 193. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product and Services
Table 194. Inovio Pharmaceuticals Inc Recent Developments
Table 195. Kineta Inc Company Information
Table 196. Kineta Inc Description and Overview
Table 197. Kineta Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 198. Kineta Inc Influenzavirus B Infection Drug Product and Services
Table 199. Kineta Inc Recent Developments
Table 200. Medicago Inc Company Information
Table 201. Medicago Inc Description and Overview
Table 202. Medicago Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 203. Medicago Inc Influenzavirus B Infection Drug Product and Services
Table 204. Medicago Inc Recent Developments
Table 205. MedImmune LLC Company Information
Table 206. MedImmune LLC Description and Overview
Table 207. MedImmune LLC Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 208. MedImmune LLC Influenzavirus B Infection Drug Product and Services
Table 209. MedImmune LLC Recent Developments
Table 210. Mucosis BV Company Information
Table 211. Mucosis BV Description and Overview
Table 212. Mucosis BV Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 213. Mucosis BV Influenzavirus B Infection Drug Product and Services
Table 214. Mucosis BV Recent Developments
Table 215. Novavax Inc Company Information
Table 216. Novavax Inc Description and Overview
Table 217. Novavax Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 218. Novavax Inc Influenzavirus B Infection Drug Product and Services
Table 219. Novavax Inc Recent Developments
Table 220. Park Active Molecules Company Information
Table 221. Park Active Molecules Description and Overview
Table 222. Park Active Molecules Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 223. Park Active Molecules Influenzavirus B Infection Drug Product and Services
Table 224. Park Active Molecules Recent Developments
Table 225. Romark Laboratories LC Company Information
Table 226. Romark Laboratories LC Description and Overview
Table 227. Romark Laboratories LC Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 228. Romark Laboratories LC Influenzavirus B Infection Drug Product and Services
Table 229. Romark Laboratories LC Recent Developments
Table 230. Sanofi Company Information
Table 231. Sanofi Description and Overview
Table 232. Sanofi Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 233. Sanofi Influenzavirus B Infection Drug Product and Services
Table 234. Sanofi Recent Developments
Table 235. Sanofi Pasteur SA Company Information
Table 236. Sanofi Pasteur SA Description and Overview
Table 237. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 238. Sanofi Pasteur SA Influenzavirus B Infection Drug Product and Services
Table 239. Sanofi Pasteur SA Recent Developments
Table 240. Shionogi & Co Ltd Company Information
Table 241. Shionogi & Co Ltd Description and Overview
Table 242. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 243. Shionogi & Co Ltd Influenzavirus B Infection Drug Product and Services
Table 244. Shionogi & Co Ltd Recent Developments
Table 245. SK Chemicals Co Ltd Company Information
Table 246. SK Chemicals Co Ltd Description and Overview
Table 247. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 248. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product and Services
Table 249. SK Chemicals Co Ltd Recent Developments
Table 250. TSRL Inc Company Information
Table 251. TSRL Inc Description and Overview
Table 252. TSRL Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 253. TSRL Inc Influenzavirus B Infection Drug Product and Services
Table 254. TSRL Inc Recent Developments
Table 255. Vaxart Inc Company Information
Table 256. Vaxart Inc Description and Overview
Table 257. Vaxart Inc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 258. Vaxart Inc Influenzavirus B Infection Drug Product and Services
Table 259. Vaxart Inc Recent Developments
Table 260. Vectura Group Plc Company Information
Table 261. Vectura Group Plc Description and Overview
Table 262. Vectura Group Plc Influenzavirus B Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 263. Vectura Group Plc Influenzavirus B Infection Drug Product and Services
Table 264. Vectura Group Plc Recent Developments
Table 265. Key Raw Materials Lists
Table 266. Raw Materials Key Suppliers Lists
Table 267. Influenzavirus B Infection Drug Distributors List
Table 268. Influenzavirus B Infection Drug Customers List
Table 269. Influenzavirus B Infection Drug Market Trends
Table 270. Influenzavirus B Infection Drug Market Drivers
Table 271. Influenzavirus B Infection Drug Market Challenges
Table 272. Influenzavirus B Infection Drug Market Restraints
Table 273. Research Programs/Design for This Report
Table 274. Key Data Information from Secondary Sources
Table 275. Key Data Information from Primary Sources
List of Figures
Figure 1. Influenzavirus B Infection Drug Product Picture
Figure 2. Global Influenzavirus B Infection Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Influenzavirus B Infection Drug Market Share by Type in 2024 & 2034
Figure 4. APP-309 Product Picture
Figure 5. CF-403 Product Picture
Figure 6. GC-3106A Product Picture
Figure 7. KIN-1400 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Influenzavirus B Infection Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 10. Global Influenzavirus B Infection Drug Market Share by Application in 2024 & 2034
Figure 11. Clinic
Figure 12. Hospital
Figure 13. Others
Figure 14. Influenzavirus B Infection Drug Report Years Considered
Figure 15. Global Influenzavirus B Infection Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 16. Global Influenzavirus B Infection Drug Revenue 2018-2034 (US$ Million)
Figure 17. Global Influenzavirus B Infection Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 18. Global Influenzavirus B Infection Drug Sales Quantity 2018-2034 (K Pcs)
Figure 19. Global Influenzavirus B Infection Drug Sales Quantity Market Share by Region (2018-2023)
Figure 20. Global Influenzavirus B Infection Drug Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Influenzavirus B Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 22. North America Influenzavirus B Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Influenzavirus B Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 24. Europe Influenzavirus B Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Influenzavirus B Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 26. China Influenzavirus B Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Influenzavirus B Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 28. APAC Influenzavirus B Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Influenzavirus B Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 30. Middle East, Africa and Latin America Influenzavirus B Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Influenzavirus B Infection Drug Sales Quantity in 2024
Figure 32. The Top 10 and Top 5 Players Market Share by Influenzavirus B Infection Drug Revenue in 2024
Figure 33. Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 34. Global Influenzavirus B Infection Drug Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2018-2034)
Figure 36. Global Influenzavirus B Infection Drug Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2018-2034)
Figure 38. North America Influenzavirus B Infection Drug Revenue Market Share by Company in 2024
Figure 39. North America Influenzavirus B Infection Drug Sales Quantity Market Share by Company in 2024
Figure 40. North America Influenzavirus B Infection Drug Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Influenzavirus B Infection Drug Revenue Market Share by Type (2018-2034)
Figure 42. North America Influenzavirus B Infection Drug Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Influenzavirus B Infection Drug Revenue Market Share by Application (2018-2034)
Figure 44. North America Influenzavirus B Infection Drug Revenue Share by Country (2018-2034)
Figure 45. North America Influenzavirus B Infection Drug Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. Influenzavirus B Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Influenzavirus B Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Influenzavirus B Infection Drug Sales Quantity Market Share by Company in 2024
Figure 49. Europe Influenzavirus B Infection Drug Revenue Market Share by Company in 2024
Figure 50. Europe Influenzavirus B Infection Drug Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Influenzavirus B Infection Drug Revenue Market Share by Type (2018-2034)
Figure 52. Europe Influenzavirus B Infection Drug Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Influenzavirus B Infection Drug Revenue Market Share by Application (2018-2034)
Figure 54. Europe Influenzavirus B Infection Drug Revenue Share by Country (2018-2034)
Figure 55. Europe Influenzavirus B Infection Drug Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Influenzavirus B Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 57. France Influenzavirus B Infection Drug